Answers are grounded in this paper and cite their sources.
Background: Clinical usefulness of trazodone for delirium in patients receiving palliative care is unclear. Objectives: To examine the safety and effectiveness of trazodone for delirium. Design: A secondary analysis of a multicenter prospective observational study. Setting/Subjects: The setting involves nine psycho-oncology consultation services and 14 inpatient palliative care units in Japan. Measurements: The measurement involves the Delirium Rating Scale (DRS) Revised-98 for effectiveness and the CTCAE (Common Terminology Criteria for Adverse Events) version 4 for safety assessments. Results: Thirty-eight patients enrolled the study. Mean age was 75 years. After three-day observation, the DRS total score (11.6 ± 5.3 to 8.7 ± 6.5 [difference −2.9, 95% confidence interval −5.3 to −0.5, p = 0.02]); sleep–wake cycle disturbance ( p = 0.047), lability of affect ( p < 0.001), and motor agitation subscales ( p < 0.001) were significantly decreased. The most frequent adverse event was somnolence ( n = 9). Conclusions: Low-dose trazodone treatment was generally safe and may be effective in reducing delirium severity.
No takes yet. Share an insight, caveat, or question.
Maeda et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: